8.61
price up icon0.70%   0.06
after-market 시간 외 거래: 8.36 -0.25 -2.90%
loading

Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스

pulisher
02:50 AM

Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday - MarketBeat

02:50 AM
pulisher
02:50 AM

Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat

02:50 AM
pulisher
04:03 AM

Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com

04:03 AM
pulisher
Oct 31, 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 29, 2024

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

How To Trade (ZVRA) - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 22, 2024

Will Zevra Gallop Or Saunter In Q3? - RTTNews

Oct 22, 2024
pulisher
Oct 17, 2024

Objective long/short (ZVRA) Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 17, 2024

Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 14, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 14, 2024
pulisher
Oct 13, 2024

Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $20.83 - MarketBeat

Oct 13, 2024
pulisher
Oct 13, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 25.7% in September - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

A company insider recently bought 2,000 shares of Zevra Therapeutics Inc [ZVRA]. Should You Buy? - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 10, 2024
pulisher
Oct 10, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented - EIN News

Oct 10, 2024
pulisher
Oct 09, 2024

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders - The Manila Times

Oct 09, 2024
pulisher
Oct 08, 2024

When Will Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Breakeven? - Simply Wall St

Oct 08, 2024
pulisher
Oct 07, 2024

Guggenheim Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

(ZVRA) Proactive Strategies - Stock Traders Daily

Oct 06, 2024
pulisher
Oct 02, 2024

HC Wainwright Comments on Zevra Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ZVRA) - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

HC Wainwright Weighs in on Zevra Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ZVRA) - MarketBeat

Oct 02, 2024
pulisher
Oct 01, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Given Overweight Rating at Cantor Fitzgerald - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

Brokers Issue Forecasts for Zevra Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ZVRA) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Zevra Therapeutics' SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Zevra Therapeutics shares keep Buy rating on FDA approval By Investing.com - Investing.com Canada

Sep 30, 2024
pulisher
Sep 30, 2024

Zevra Therapeutics' SWOT analysis: rare disease focus drives stock potential - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Zevra Therapeutics shares keep Buy rating on FDA approval - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat

Sep 30, 2024
pulisher
Sep 29, 2024

The week in pharma: action, reaction and insight – week to September 27 | Biotechnology | The Pharmaletter - The Pharma Letter

Sep 29, 2024
pulisher
Sep 26, 2024

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to Post FY2024 Earnings of ($1.57) Per Share, Roth Capital Forecasts - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Zevra to Present Phase 2 Data on KP1077 for Idiopathic Hypersomnia - Sleep Review

Sep 26, 2024
pulisher
Sep 26, 2024

(ZVRA) Long Term Investment Analysis - Stock Traders Daily

Sep 26, 2024
pulisher
Sep 25, 2024

Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com Australia

Sep 25, 2024
pulisher
Sep 25, 2024

Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com Australia

Sep 25, 2024
pulisher
Sep 25, 2024

Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld Online

Sep 25, 2024
pulisher
Sep 24, 2024

US FDA approves IntraBio's drug for rare genetic disease - Reuters

Sep 24, 2024
pulisher
Sep 24, 2024

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics share price target lifted, buy rating held on FDA approval - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Analysts at JMP Securities - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Increased to $21.00 by Analysts at Roth Mkm - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics Mixed Q2 Results: Details - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics price target raised to $25 from $18 at Maxim - TipRanks

Sep 24, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):